IGA NEPHROPATHY
Clinical trials for IGA NEPHROPATHY explained in plain language.
Never miss a new study
Get alerted when new IGA NEPHROPATHY trials appear
Sign up with your email to follow new studies for IGA NEPHROPATHY, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New shot aims to tame rare kidney disease in Mid-Stage trial
Disease control Not yet recruitingThis study tests a new drug, CM313, in 106 adults with IgA nephropathy, a kidney disease that can lead to kidney failure. The goal is to see if the drug is safe and helps control the disease. Participants will receive the drug as a shot, and researchers will monitor side effects …
Matched conditions: IGA NEPHROPATHY
Phase: PHASE2 • Sponsor: Keymed Biosciences Co.Ltd • Aim: Disease control
Last updated Apr 29, 2026 04:27 UTC
-
New hope for kidney disease: JADE101 trial launches
Disease control Not yet recruitingThis study tests a new drug called JADE101 in 30 adults with IgA nephropathy, a kidney disease. The goal is to see if the drug is safe and can reduce protein in the urine, which is a sign of kidney damage. Participants must be on stable standard treatment before joining.
Matched conditions: IGA NEPHROPATHY
Phase: PHASE2 • Sponsor: Jade Biosciences, Inc. • Aim: Disease control
Last updated Apr 29, 2026 04:27 UTC